Accenture CEO Julie Sweet Diagnosed with Early-Stage Breast Cancer, Prognosis is ‘Excellent’:

Accenture CEO Julie Sweet has been diagnosed with early-stage breast cancer, with treatment expected to last between 12 to 16 weeks, according to an internal memo obtained by Moneycontrol.

Despite the diagnosis, Sweet assured employees that her prognosis is excellent, as the cancer was caught early and is completely curable.

“I was very recently diagnosed with breast cancer. The good news is that the prognosis from my doctor is excellent; the cancer was caught early, and my condition is curable,” Sweet wrote in an email to Accenture employees.

She also confirmed that scans showed no evidence of cancer elsewhere in her body.

Julie Sweet to Continue Leading Accenture During Treatment

An Accenture spokesperson reaffirmed that Sweet will continue to lead the company’s day-to-day operations while undergoing treatment.

"As stated in the memo Julie sent to our people, her prognosis is excellent, the cancer was caught early, and her condition is curable. She will work substantially as normal and continue to lead the day-to-day operation of the company," the spokesperson told Moneycontrol.

Sweet is scheduled to undergo surgery next week, followed by radiation therapy as part of her treatment plan.

While she will reduce travel commitments, Accenture’s Board of Directors is fully briefed and supportive of her decision to continue in her role.

Confident in Accenture’s Leadership Team

Sweet expressed confidence in Accenture’s Global Management Committee and the company’s ability to continue delivering value to clients and stakeholders.

“We have an incredible Global Management Committee, supported by our amazing teams around the world. I am confident that we will continue to do what we do best—deliver 360° value for our clients, people, shareholders, partners, and communities.”

Despite the challenges ahead, Sweet’s leadership remains strong and steadfast, ensuring business continuity while focusing on her health.